Bambusa Initiates Subcutaneous BBT001 Dosing in Atopic Dermatitis
Bambusa Therapeutics has initiated subcutaneous dosing of BBT001 in atopic dermatitis, transitioning from an intravenous proof-of-concept phase the sponsor called 'compelling.'
Topic
Subcutaneous Biologic
Topic